Selinexor (KPT-330)

For research use only.

Catalog No.S7252 Synonyms: ATG-010

33 publications

Selinexor (KPT-330) Chemical Structure

CAS No. 1393477-72-9

Selinexor (KPT-330, ATG-010) is an orally bioavailable selective CRM1 inhibitor. Phase 2.

Size Price Stock Quantity  
EUR 95 In stock
EUR 560 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Selinexor (KPT-330) has been cited by 33 publications

Purity & Quality Control

Choose Selective CRM1 Inhibitors

Biological Activity

Description Selinexor (KPT-330, ATG-010) is an orally bioavailable selective CRM1 inhibitor. Phase 2.
CRM1 [1]
(Cell-free assay)
In vitro

As the clinical candidate analog of KPT-185, KPT-330 exhibits similar effects on the viability of T-ALL cells and elicits rapid apoptotic response. KPT-330 also reduces cell growth in MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines, with IC50 values of 34-203 nM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT474 cells MkDNSpVv[3Srb36gZZN{[Xl? M1iye|AvOSEQvF2= NWHs[nQ4OjRiaDDvdkA1QCCq NWTuUFlkcW6mdXPld{BlcW[oZYLlcpRq[WxiQXv0JJNq\26jbHnu[{0h[W6mIH3leIFjd2yrc32tZZN{d2OrYYTl[EBo\W6nIHX4dJJme3Orb36gdJJw\mmuZYOu M3nzcFMxQTh5M{iw
MCF-7 MlfRSpVv[3Srb36gZZN{[Xl? NHu3cXMxNjFizszN MXmyOEBpKG:{IES4JIg> NITtTYdqdmS3Y3XzJIRq\m[ncnXueIlidCCDa4Sgd4lodmGuaX7nMUBidmRibXX0ZYJwdGm|bT3hd5Nw[2mjdHXkJIdmdmViZYjwdoV{e2mxbjDwdo9ncWyncz6= M{HvelMxQTh5M{iw
THP-1 MVrGeY5kfGmxbjDhd5NigQ>? MlHhNlQhcA>? MkLpR4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[UA{KHencnWgd5Rzd26pbImg[Y5p[W6lZXSgbY4hfGinIHPvcYJqdmG2aX;uJJRz\WG2bXXueEB4cGWwIHPvcZBiemWmIITvJGFDXC1zOUmgc5IhU1CWLUOzNEBidG:wZR?= MWKzNFU6PjN7OB?=
OCI-AML3 MnjFSpVv[3Srb36gZZN{[Xl? NWTMVG9UOjRiaB?= MkDuR4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[UA{KHencnWgd5Rzd26pbImg[Y5p[W6lZXSgbY4hfGinIHPvcYJqdmG2aX;uJJRz\WG2bXXueEB4cGWwIHPvcZBiemWmIITvJGFDXC1zOUmgc5IhU1CWLUOzNEBidG:wZR?= NUHFU2R[OzB3OU[zPVg>
MV4-11 NU\KbXduTnWwY4Tpc44h[XO|YYm= MoPvNlQhcA>? M2S2V2Nt\WG4YXflJI9nKFCDUmCgZY5lKGOjc4Dhd4UhOyC5ZYLlJJN1em:wZ3z5JIVvcGGwY3XkJIlvKHSqZTDjc41jcW6jdHnvckB1emWjdH3lcpQhf2inbjDjc41x[XKnZDD0c{BCSlRvMUm5JI9zKEuSVD2zN|Ah[WyxbnW= M4XyUFMxPTl4M{m4
T24 NYfqeHpRS2WubDD2bYFjcWyrdImgZZN{[Xl? NVL2N3I1OCxiMD6wNUwhOC5zLDCxJO69VQ>? MYW3NkBp M3[4OoNmdGxidnnhZoltcXS7IHTlZ5Jm[XOnZDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MXOzNFM1QTZ3MB?=
J82 M2TNVGNmdGxidnnhZoltcXS7IHHzd4F6 Mn[xNEwhOC5yMTygNE4yNCBzIN88US=> MYm3NkBp MnHjZ4VtdCC4aXHibYxqfHliZHXjdoVie2WmIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{fiU|MxOzR7NkWw
UM-UC-3 NY\kXIdKS2WubDD2bYFjcWyrdImgZZN{[Xl? NHrHbXoxNCByLkCxMEAxNjFuIEGg{txO MlzRO|IhcA>? NVTWXIhJ[2WubDD2bYFjcWyrdImg[IVkemWjc3XkJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MWWzNFM1QTZ3MB?=

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
CHEK1 / MLH1 / MSH2 / PMS2 / Rad51; 

PubMed: 30112106     

Western blot of proteins from whole cell lysates of HT1080 cells treated with 0, 0.1, or 1 μM selinexor and ASPS-KY cells treated with 0, 1, or 10 μM selinexor confirmed the RPPA results suggesting down-regulation of CHEK1, MLH1, MSH2, PMS2 and Rad51 protein levels from selinexor treatment in both cell lines.

XPO1 / Cyclin B1 / Cyclin D1 / c-Myc / c-Met / Mcl-1 / p21 Waf1/Cip1 / p53/ Cleaved PARP / Cleaved caspase-9 / Cleaved caspase-3 / Aurora-B; 

PubMed: 28852098     

OGK-M, HTH83, CAL62 and T238 cells were treated with either selinexor (1,000 nM) or DMSO for 24 h. Lysates were analyzed by western blot analysis for the indicated cell cycle and apoptosis proteins (GAPDH, internal loading control).

AXL / phospho-AKT / phospho-P70S6K / AKT / P70S6K; 

PubMed: 28852098     

HTH83 and CAL62 cells were cultured with either selinexor (1,000 nM) or diluent control (DMSO) for 24 h, and the whole-cell lysate was subjected to western blot analysis for AXL, p-AKT, total AKT, p-P70S6K and total P70S6K.

p53 / CDKN1a / Survivin; 

PubMed: 25948791     

Representative western immunoblotting showing nuclear and cytosolic fractions of XPO1/ CRM1, p53, CDKN1a and survivin in DMPM cells exposed to selinexor (IC50). β-actin and TBP were used to confirm equal protein loading on the gel and to show the relative purity of the nuclear fractions.

30112106 28852098 25948791
XPO1 / tubulin; 

PubMed: 30349650     

Immunofluorescent detection of XPO1 (green) in cells treated with vehicle and selinexor. Cells were plated on chamber slides and they were treated with either vehicle or selinexor for 48 hours. Tubulin (red) and DAPI (blue) served to define the nuclear and cytoplasmic compartment, respectively. V = vehicle, S = selinexor.

NPM1 / PU.1; 

PubMed: 30015632     

IF for NPM1 and PU.1 in vehicle- versus selinexor-treated NPM1-mutated AML cells. DAPI was used to stain for nuclei. Images by Nikon Eclipse 400 microscope; original magnification, ×630.

30349650 30015632
Growth inhibition assay
Cell viability; 

PubMed: 28852098     

Cells were treated with selinexor at indicated concentrations for 72 h, and growth inhibition was measured by MTT assay. Results are expressed as mean value ± SD; n = 4. 

In vivo KPT-330 dramatically suppresses the growth of T-ALL cells (MOLT-4) and AML cells (MV4–11) in vivo, with little toxicity to normal haematopoietic cells. [1] In SCID mice with diffuse human MM bone lesions, KPT-330 inhibits MM-induced bone lysis and prolongs survival. Moreover, KPT-330 directly impairs osteoclastogenesis and bone resorption by blocking RANKL-induced NF-κB and NFATc1, with minimal impact on osteoblasts and BMSCs. [2]


Cell Research:[1]
- Collapse
  • Cell lines: MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines
  • Concentrations: ~1 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cell Titer Glo assay is used to assess cell viability upon treatment with either dimethyl sulfoxide (DMSO) or KPT-330. Cells are plated at a density of 10 000 cells per well in a 96-well plate and incubated with DMSO or increasing concentrations of KPT-330. The cell viability is measured after 72 h exposure to KPT-330 and reported as a percentage of DMSO control cells. Jurkat cells that overexpress BCL2 are generated using MSCV-IRES-GFP retroviral expression system. Jurkat cells infected with BCL2 or control vector viruses are sorted by flow cytometry and the expression of BCL2 confirmed by Western blot analysis using BCL2 antibody.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: T-ALL and AML orthograft mouse model
  • Dosages: 20 -25 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 88 mg/mL (198.5 mM)
Water Insoluble
Ethanol ''40 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+40%PEG 300+5% Tween80 +ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.31


CAS No. 1393477-72-9
Storage powder
in solvent
Synonyms ATG-010
Smiles C1=CN=C(C=N1)NNC(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02091245 Active not recruiting Drug: KPT-330 Relapsed Acute Lymphoblastic Leukemia (ALL)|Refractory Acute Lymphoblastic Leukemia (ALL)|Relapsed Acute Myelogenous Leukemia (AML)|Refractory Acute Myelogenous Leukemia (AML)|Relapsed Mixed Lineage Leukemia|Refractory Mixed Lineage Leukemia|Relapsed Biphenotypic Leukemia|Refractory Biphenotypic Leukemia|Chronic Myelogenous Leukemia (CML) in Blast Crisis Dana-Farber Cancer Institute|William Lawrence and Blanche Hughes Foundation|Karyopharm Therapeutics Inc March 2014 Phase 1
NCT02078349 Unknown status Drug: KPT-330 Solid Tumors National University Hospital Singapore|Karyopharm Therapeutics Inc February 2014 Phase 1
NCT02025985 Completed Drug: Selinexor Ovarian Carcinoma|Endometrial Carcinoma|Cervical Carcinoma|Breast Cancer Karyopharm Therapeutics Inc January 2014 Phase 2
NCT01896505 Completed Drug: KCP-330 Sarcoma Karyopharm Therapeutics Inc July 2013 Phase 1
NCT01607905 Completed Drug: KPT-330 Solid Tumor Karyopharm Therapeutics Inc June 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Selinexor (KPT-330) | Selinexor (KPT-330) supplier | purchase Selinexor (KPT-330) | Selinexor (KPT-330) cost | Selinexor (KPT-330) manufacturer | order Selinexor (KPT-330) | Selinexor (KPT-330) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID